about
Potential role of miR-9 and miR-223 in recurrent ovarian cancerThe Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerSniffing out significant "Pee values": genome wide association study of asparagus anosmiaDevelopment and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), standardized documentation, sample and data release, and international perspectiveReal-time analysis of beta- and gamma-catenin mRNA expression in ret/PTC-1 activated and nonactivated thyroid tissues.Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients.Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines.A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.Systems-level modeling of cancer-fibroblast interaction.Circular RNAs: Biogenesis, Function and Role in Human Diseases.The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progressionPlatelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.Genetic variation in RNASEL associated with prostate cancer risk and progression.SPINK1 protein expression and prostate cancer progression.Immunohistochemical expression of BRCA1 and lethal prostate cancer.Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapyFOXA1 is a potential oncogene in anaplastic thyroid carcinoma.mRNA expression signature of Gleason grade predicts lethal prostate cancerDNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancerTumor expression of adiponectin receptor 2 and lethal prostate cancerCannonball metastases with favourable prognosis.Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate CancerUtility of multispectral imaging in automated quantitative scoring of immunohistochemistry.Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment.Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolutionDietary lycopene intake and risk of prostate cancer defined by ERG protein expressionGolgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion.A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancerGleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERGProstate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLCMolecular testing in oncology: problems, pitfalls and progress.Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells.Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.The role of DNA repair pathways in cisplatin resistant lung cancer.
P50
Q21245724-F18B1C7E-2D9E-41FD-8866-AC7A37E35CBEQ26738703-3DB5E0FF-4739-420A-9A76-D727D1D1CAB0Q28587577-63CF42CB-80E1-4DF0-BA7B-6CEB86A025BDQ28656456-574C944C-35CA-4916-9484-F39002E53308Q31133084-6309276F-307E-458D-B72D-434C7A25E5A4Q33233632-71736BD4-C465-4D3D-AF82-6AF56541C48BQ33269396-33F43FC7-DE87-4AFC-8689-ACBA68F7643BQ33292141-20FB5BA0-22E4-4E51-BB55-A697D525E4FBQ33421665-265AFA38-171E-457C-AD3F-942DA74720ACQ33499686-051B075B-B034-4D9E-81AD-839F72D7855FQ33766123-DDD9030B-2BFE-4087-BBAE-DA05D6F0BEA0Q33825555-9D3342A0-87DC-4B73-9715-9603C20726E8Q33934897-98D3172D-455E-4EA5-AB44-E816435263A7Q34056033-EA3A022E-6629-48B4-8C6C-B164F6DBE0A8Q34094981-A996409E-40C1-4BE2-A06F-BED854E392CAQ34203149-D8A87B38-2400-4811-A128-68712A0E0276Q34626692-A4B02E66-958D-42C0-A554-EA2F1A3AFE1CQ34674928-F94EBD6B-95E0-447B-B936-929DD3D1F34FQ34983133-7851988B-8799-4674-AF06-4AE2D2653707Q35023464-6AE9E821-BEAD-4F71-9D99-3D33982FD755Q35206363-50D90841-B8B9-4D67-B47A-F8158251C37CQ35784565-592FF511-7DD0-4E08-A8E9-4963FFCF5CDAQ36115062-6EAC2967-864C-452A-8A56-9FD36E3A50CDQ36199762-60412FE2-91BC-4C8C-A966-37161D17716EQ36221055-478D4A0B-9D08-4C8C-BB65-AA6B0F1CC307Q36241604-21FAC5CD-0699-4977-98D8-5EEFDB15835DQ36471600-C70EF620-9E21-4187-B432-1BF519046CFCQ36606672-878CCB27-2634-4492-9DA7-A98B1A1DE8ECQ36750617-B70A34F0-7F48-42C4-B190-35F753B54B1EQ36887707-9938ED29-5519-4C9C-AB15-B81FA658F5BEQ37170747-43825C51-C233-4FD6-B0D2-1D031426696DQ37280719-4F212B0E-1E67-4EE6-815D-3185B5029C5CQ37282349-075A652B-1C14-450B-AA90-3C53F8784371Q37399337-5CF3C717-1BC1-4652-8EBB-4D9ADD775FFCQ37486567-226859E9-821A-4B7E-BF49-514682589C8EQ37694812-B3B98AA6-5CC7-47E4-ACE7-418CBEB4EC82Q38182743-399D866C-25C7-46CE-B706-4135DB33784BQ38187487-D79A22F8-D170-4FDB-8967-85A5A14AD94AQ38202357-844FE653-1DE4-486C-B9B1-84097FA975AAQ38280128-8B942B8A-1B79-4563-92E6-A8AA9C8F8413
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stephen P. Finn
@ast
Stephen P. Finn
@en
Stephen P. Finn
@es
Stephen P. Finn
@nl
Stephen P. Finn
@sl
type
label
Stephen P. Finn
@ast
Stephen P. Finn
@en
Stephen P. Finn
@es
Stephen P. Finn
@nl
Stephen P. Finn
@sl
altLabel
Stephen Finn
@en
prefLabel
Stephen P. Finn
@ast
Stephen P. Finn
@en
Stephen P. Finn
@es
Stephen P. Finn
@nl
Stephen P. Finn
@sl
P1053
G-9397-2014
P106
P1153
7101623347
P21
P2798
P31
P3829
P496
0000-0002-8628-5814